Igor L. Bado

Igor L. Bado

Auto-generated profile, based on publicly available information

Igor L. Bado

Icahn School of Medicine at Mount Sinai 12 , New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSSwarnima Singh
Swarnima Singh
NLNigel Lee
Nigel Lee
DPDiego Pedroza
Diego Pedroza
IBIgor L. Bado
Igor L. Bado
CHClark Hamor
Clark Hamor
JRJeffrey Rosen
Jeffrey Rosen
Immunosuppressive elements within the tumor microenvironment, such as tumor-associated macrophages (TAM), can present a barrier to successful antitumor responses by cytolytic T cells. Here we employed preclinical syngeneic p53 null mouse models of triple-negative breast cancer (TNBC) to develop a treatment regimen that harnessed the immunostimulatory effects of low-dose cyclophosphamide coupled with the pharmacologic inhibition of TAMs using either a small-molecule CSF1R inhibitor or an anti-CSF1R antibody. This therapeutic combination was effective in treating several highly aggressive TNBC murine mammary tumor and lung metastasis models. Single-cell RNA sequencing characterized tumor-infiltrating lymphocytes including Th cells and antigen-presenting B cells that were highly enriched in responders to combination therapy. In one model that exhibited long-term posttreatment tumor regression, high-dimensional imaging techniques identified the close spatial localization of B220+/CD86+-activated B cells and CD4+ T cells in tertiary lymphoid structures that were present up to 6 weeks posttreatment. The transcriptional and metabolic heterogeneity of TAMs was also characterized in two closely related claudin-low/mesenchymal subtype tumor models with differential treatment responses. A murine TAM signature derived from the T12 model was highly conserved in human claudin-low breast cancers, and high expression of the TAM signature correlated with reduced overall survival in patients with breast cancer. This TAM signature may help identify human patients with claudin-low breast cancer that will benefit from the combination of cyclophosphamide and anti-CSF1R therapy. These studies illustrate the complexity of the tumor immune microenvironment and highlight different immune responses that result from rational immunotherapy combinations. Significance: Immunostimulatory chemotherapy combined with pharmacologic inhibition of TAMs results in durable treatment responses elicited by Th cells and B cells in claudin-low TNBC models.

26 October 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
WZWeijie Zhang
Weijie Zhang
ZXZhan Xu
Zhan Xu
XHXiaoxin Hao
Xiaoxin Hao
THTiancheng He
Tiancheng He
JLJiasong Li
Jiasong Li
XZXiang H.-F. Zhang
Xiang H.-F. Zhang
The bone microenvironment is dynamic and undergoes remodeling in normal and pathologic conditions. Whether such remodeling affects disseminated tumor cells (DTC) and bone metastasis remains poorly understood. Here, we demonstrated that pathologic fractures increase metastatic colonization around the injury. NG2+ cells are a common participant in bone metastasis initiation and bone remodeling in both homeostatic and fractured conditions. NG2+ bone mesenchymal stem/stromal cells (BMSC) often colocalize with DTCs in the perivascular niche. Both DTCs and NG2+ BMSCs are recruited to remodeling sites. Ablation of NG2+ lineage impaired bone remodeling and concurrently diminished metastatic colonization. In cocultures, NG2+ BMSCs, especially when undergoing osteodifferentiation, enhanced cancer cell proliferation and migration. Knockout of N-cadherin in NG2+ cells abolished these effects in vitro and phenocopied NG2+ lineage depletion in vivo. These findings uncover dual roles of NG2+ cells in metastasis and remodeling and indicate that osteodifferentiation of BMSCs promotes metastasis initiation via N-cadherin–mediated cell–cell interaction. Significance: The bone colonization of cancer cells occurs in an environment that undergoes constant remodeling. Our study provides mechanistic insights into how bone homeostasis and pathologic repair lead to the outgrowth of disseminated cancer cells, thereby opening new directions for further etiologic and epidemiologic studies of tumor recurrences. This article is highlighted in the In This Issue feature, p. 247

21 January 2025 in Cancer Discovery
Verified
Journal Article
Closed access
RARahat Alam
Rahat Alam
ARAnna Reva
Anna Reva
DEDavid G. Edwards
David G. Edwards
BLBree M. Lege
Bree M. Lege
LMLaura S. Munoz-Arcos
Laura S. Munoz-Arcos
IBIgor L. Bado
Igor L. Bado
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer. Significance: Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.

1 July 2026 in Cancer Research
Verified
Journal Article
Closed access
LWLing Wu
Ling Wu
ZXZhan Xu
Zhan Xu
JWJun Wang
Jun Wang
FLFengshuo Liu
Fengshuo Liu
YDYunfeng Ding
Yunfeng Ding
XZXiang H.-F. Zhang
Xiang H.-F. Zhang
Neutrophils are a prominent component of the tumor microenvironment (TME) that can have both pro- and antitumor functions. By analyzing neutrophils across different human cancers, we revealed an ICAM1high subset enriched in the TME, which was also observed in murine triple-negative breast cancer (TNBC) models. ICAM1high neutrophils exhibited an enhanced capacity for cell–cell adhesion specifically with tumor cells retaining epithelial features, and this adhesion conferred mutual advantages to both cell types. In contrast, cancer cells with mesenchymal-like phenotypes were vulnerable to neutrophil-mediated cytotoxicity due to decreased cell adhesion and elastase resistance. These opposite effects drove tumor evolution toward a dichotomy of neutrophil-enriched, epithelial-like ecosystems and macrophage-enriched, mesenchymal-like ecosystems. As ICAM1high neutrophils can reverse migrate from tissue into the circulation, the adhesive and reverse migratory properties together mediate metastatic intravasation. Spatial transcriptomic and tissue microarray analyses demonstrated interactions between tumor cells, neutrophils, and endothelial cells in human TNBC, particularly in non-Hispanic Europeans compared with African American patients. Together, this study demonstrated tumor–immune coevolution in which neutrophils instruct the phenotypes and metastatic behaviors of TNBC, which may preferentially occur in patients of certain ancestries. Significance: A distinct subset of ICAMhigh tumor-infiltrating neutrophils with increased adhesion and reverse transendothelial migration shapes tumor phenotypes and metastatic potential through mutually beneficial interactions with epithelial cancer cells.

4 April 2023
Verified
Other
Open access
WZWeijie Zhang
Weijie Zhang
ZXZhan Xu
Zhan Xu
XHXiaoxin Hao
Xiaoxin Hao
THTiancheng He
Tiancheng He
JLJiasong Li
Jiasong Li
XZXiang H.-F. Zhang
Xiang H.-F. Zhang
Supplemantary Video 3, LLC1 cells cocultured with NG2- BMSCs

4 April 2023
Verified
Other
Open access
WZWeijie Zhang
Weijie Zhang
ZXZhan Xu
Zhan Xu
XHXiaoxin Hao
Xiaoxin Hao
THTiancheng He
Tiancheng He
JLJiasong Li
Jiasong Li
XZXiang H.-F. Zhang
Xiang H.-F. Zhang
Supplemantary Video 2, LLC1 cells under monoculture